Screener
Tango Therapeutics TNGX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
FAQ
- What is Tango Therapeutics's cash & equivalents?
- Tango Therapeutics (TNGX) reported cash & equivalents of $159.97M in Q1 2026.
- How has Tango Therapeutics's cash & equivalents changed year-over-year?
- Tango Therapeutics's cash & equivalents increased by 162.2% year-over-year, from $61M to $159.97M.
- What is the long-term trend for Tango Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Tango Therapeutics's cash & equivalents has grown at a 143.9% compound annual growth rate (CAGR), from $1.3M to $112.28M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Tango Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude